In a few days, the U.S. Food and Drug Administration (FDA) is expected to announce whether or not it decided that aducanumab, an investigational treatment for Alzheimer’s disease developed by Biogen, merits approval and wide clinical use. The medication’s review marks the first time in nearly two decades that the FDA has considered approving a potential Alzheimer’s treatment. If aducanumab is given a green light, it would become the first disease-modifying therapy for Alzheimer’s in…
You must be logged in to read/download the full post.
The post Alzheimer’s Association on Aducanumab: Chance for ‘More Time’ Merits Approval appeared first on BioNewsFeeds.